376 related articles for article (PubMed ID: 16075043)
1. Genetics of acquired long QT syndrome.
Roden DM; Viswanathan PC
J Clin Invest; 2005 Aug; 115(8):2025-32. PubMed ID: 16075043
[TBL] [Abstract][Full Text] [Related]
2. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
3. The inherited long QT syndrome: from ion channel to bedside.
Vincent GM; Timothy K; Fox J; Zhang L
Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
[TBL] [Abstract][Full Text] [Related]
4. Cellular mechanisms of Torsade de Pointes.
Poelzing S; Rosenbaum DS
Novartis Found Symp; 2005; 266():204-17; discussion 217-24. PubMed ID: 16050270
[TBL] [Abstract][Full Text] [Related]
5. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
Vincent GM
Annu Rev Med; 1998; 49():263-74. PubMed ID: 9509262
[TBL] [Abstract][Full Text] [Related]
6. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
7. Torsade de pointes.
El-Sherif N; Turitto G
Curr Opin Cardiol; 2003 Jan; 18(1):6-13. PubMed ID: 12496496
[TBL] [Abstract][Full Text] [Related]
8. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
9. Atrioventricular block-induced Torsades de Pointes with clinical and molecular backgrounds similar to congenital long QT syndrome.
Oka Y; Itoh H; Ding WG; Shimizu W; Makiyama T; Ohno S; Nishio Y; Sakaguchi T; Miyamoto A; Kawamura M; Matsuura H; Horie M
Circ J; 2010 Nov; 74(12):2562-71. PubMed ID: 20975234
[TBL] [Abstract][Full Text] [Related]
10. Torsade de pointes: the clinical considerations.
Gowda RM; Khan IA; Wilbur SL; Vasavada BC; Sacchi TJ
Int J Cardiol; 2004 Jul; 96(1):1-6. PubMed ID: 15203254
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced long QT and torsade de pointes: recent advances.
Kannankeril PJ; Roden DM
Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
[TBL] [Abstract][Full Text] [Related]
12. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
13. Gene mutations associated with atrioventricular block complicated by long QT syndrome.
Nishizaki M; Hiraoka M
Circ J; 2010 Nov; 74(12):2546-7. PubMed ID: 21088333
[No Abstract] [Full Text] [Related]
14. Efficacy of ventricular pacing in the treatment of an arrhythmic storm associated with a congenital long QT mutation.
Aziz PF; Shah MJ
Congenit Heart Dis; 2013; 8(6):E165-7. PubMed ID: 23075154
[TBL] [Abstract][Full Text] [Related]
15. A presumably benign human ether-a-go-go-related gene mutation (R176W) with a malignant primary manifestation of long QT syndrome.
Donner BC; Marschall C; Schmidt KG
Cardiol Young; 2012 Jun; 22(3):360-3. PubMed ID: 22067087
[TBL] [Abstract][Full Text] [Related]
16. Genetic modulation of cardiac repolarization reserve.
Remme CA; Bezzina CR
Heart Rhythm; 2007 May; 4(5):608-10. PubMed ID: 17467629
[No Abstract] [Full Text] [Related]
17. Cellular mechanisms underlying the long QT syndrome.
Antzelevitch C; Shimizu W
Curr Opin Cardiol; 2002 Jan; 17(1):43-51. PubMed ID: 11790933
[TBL] [Abstract][Full Text] [Related]
18. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome.
Weeke P; Mosley JD; Hanna D; Delaney JT; Shaffer C; Wells QS; Van Driest S; Karnes JH; Ingram C; Guo Y; Shyr Y; Norris K; Kannankeril PJ; Ramirez AH; Smith JD; Mardis ER; Nickerson D; George AL; Roden DM
J Am Coll Cardiol; 2014 Apr; 63(14):1430-7. PubMed ID: 24561134
[TBL] [Abstract][Full Text] [Related]
19. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
20. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
Sun Z; Milos PM; Thompson JF; Lloyd DB; Mank-Seymour A; Richmond J; Cordes JS; Zhou J
J Mol Cell Cardiol; 2004 Nov; 37(5):1031-9. PubMed ID: 15522280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
